Session » 6W008 ACR Abstract: Pediatric Rheum–Clinical III: Assessment Tools & Biomarkers (2916–2921)

Date: Wednesday, October 24, 2018

Time: 9:00AM-10:30AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-10:30AM: Abstract Number: 2919

An Epidemic: Severe Lung Disease in Patients with Systemic Juvenile Idiopathic Arthritis, Risk Factors and Predictors

9:00AM-10:30AM: Abstract Number: 2920

Correlations of Type I Interferon Score and Interferon Induced Chemokines CXCL10 and CXCL9 with Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis

9:00AM-10:30AM: Abstract Number: 2917

Multiplex Serum Biomarker Analysis before and during Therapy with Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis

9:00AM-10:30AM: Abstract Number: 2916

New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients

9:00AM-10:30AM: Abstract Number: 2918

Physical Activity in Canadian Children with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)

9:00AM-10:30AM: Abstract Number: 2921

The Performance of the Newly Proposed EULAR/Acr Classification Criteria in Juvenile-Onset Systemic Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].